• 1
    Mendel DB, Roberts NA. In-vitro and in-vivo efficacy of influenza neuraminidase inhibitors. Curr Opin Infect Dis 1998; 11:727732.
  • 2
    Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis 2003; 188:5761.
  • 3
    Ives JA, Carr JA, Mendel DB et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002; 55:307317.
  • 4
    Dharan NJ, Gubareva LV, Meyer JJ et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009; 301:10341041.
  • 5
    Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010; 328:12721275.
  • 6
    Abed Y, Pizzorno A, Bouhy X, Boivin G. Role of permissive neuraminidase mutations in influenza A/Brisbane/59/2007-like (H1N1) viruses. PLoS Pathog 2011; 7:e1002431.
  • 7
    World Health Organization (WHO). Review of the 2011-2012 winter influenza season, northern hemisphere. Wkly Epidemiol Rec 2012; 87:23340.
  • 8
    Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Gehrig N. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N Engl J Med 2011; 365:25412542.
  • 9
    Meijer A, Jonges M, van Beek P et al. Oseltamivir-resistant influenza A(H1N1)pdm09 virus in Dutch travellers returning from Spain, August 2012. Euro Surveill 2012; 17:20266.
  • 10
    Hurt AC, Hardie K, Wilson NJ et al. Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J Infect Dis 2012; 206:148157.
  • 11
    Hurt AC, Chotpitayasunondh T, Cox NJ et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis 2012; 12:240248.
  • 12
    Storms AD, Gubareva LV, Su S et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. Emerg Infect Dis 2012; 18:308311.
  • 13
    Lackenby A, Moran Gilad J, Pebody R et al. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11. Euro Surveill 2011; 16:19784.
  • 14
    Tisdale M, Daly J, Gor D. Methods for determining resistance to neuraminidase inhibitors. Int Congr Ser 2001; 1219:879886.
  • 15
    Nguyen HT, Sheu TG, Mishin VP, Klimov AI, Gubareva LV. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob Agents Chemother 2010; 54:36713677.
  • 16
    World Health Organization (WHO). Meetings of the WHO working group on surveillance of influenza antiviral susceptibility - Geneva, November 2011 and June 2012. Wkly Epidemiol Rec 2012; 87:36974.
  • 17
    Ghedin E, Holmes EC, Depasse JV et al. Presence of oseltamivir-resistant pandemic A/H1N1 minor variants before drug therapy with subsequent selection and transmission. J Infect Dis 2012; 206:15041511.
  • 18
    Abed Y, Goyette N, Boivin G. Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations. Antimicrob Agents Chemother 2005; 49:556559.
  • 19
    Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989; 321:16961702.
  • 20
    Abed Y, Baz M, Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther 2006; 11:971976.
  • 21
    Pizzorno A, Bouhy X, Abed Y, Boivin G. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J Infect Dis 2011; 203:2531.
  • 22
    Pizzorno A, Abed Y, Bouhy X et al. Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus. Antimicrob Agents Chemother 2012; 56:12081214.
  • 23
    van der Vries E, Stelma FF, Boucher CA. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med 2010; 363:13811382.
  • 24
    Whitley RJ, Hayden FG, Reisinger KS et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20:127133.
  • 25
    Baz M, Abed Y, McDonald J, Boivin G. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 2006; 43:15551561.
  • 26
    Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 2005; 49:45154520.
  • 27
    Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998; 178:12571262.
  • 28
    Hurt AC, Holien JK, Parker M, Kelso A, Barr IG. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol 2009; 83:1036610373.
  • 29
    Dapat C, Suzuki Y, Saito R et al. Rare influenza A (H3N2) variants with reduced sensitivity to antiviral drugs. Emerg Infect Dis 2010; 16:493496.
  • 30
    Sheu TG, Deyde VM, Okomo-Adhiambo M et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008; 52:32843292.
  • 31
    McKimm-Breschkin JL, Rootes C, Mohr PG, Barrett S, Streltsov VA. In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir. J Antimicrob Chemother 2012; 67:18741883.
  • 32
    Bloom JD, Nayak JS, Baltimore D. A computational-experimental approach identifies mutations that enhance surface expression of an oseltamivir-resistant influenza neuraminidase. PLoS ONE 2011; 6:e22201.
  • 33
    Hamelin ME, Baz M, Abed Y et al. Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets. PLoS Pathog 2010; 6:e1001015.
  • 34
    Hamelin ME, Baz M, Bouhy X et al. Reduced airborne transmission of oseltamivir-resistant pandemic A/H1N1 virus in ferrets. Antivir Ther 2011; 16:775779.
  • 35
    Duan S, Boltz DA, Seiler P et al. Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog 2010; 6:e1001022.
  • 36
    Kiso M, Shinya K, Shimojima M et al. Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses. PLoS Pathog 2010; 6:e1001079.
  • 37
    Seibert CW, Kaminski M, Philipp J et al. Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. J Virol 2010; 84:1121911226.
  • 38
    Pinilla LT, Holder BP, Abed Y, Boivin G, Beauchemin CA. The H275Y neuraminidase mutation of the pandemic A/H1N1 influenza virus lengthens the eclipse phase and reduces viral output of infected cells, potentially compromising fitness in ferrets. J Virol 2012; 86:1065110660.
  • 39
    Wu WL, Lau SY, Chen Y et al. The 2008-2009 H1N1 influenza virus exhibits reduced susceptibility to antibody inhibition: implications for the prevalence of oseltamivir resistant variant viruses. Antiviral Res 2012; 93:144153.
  • 40
    Härter G, Zimmermann O, Maier L et al. Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus. Clin Infect Dis 2010; 50:12491251.
  • 41
    Hayden FG, Sable CA, Connor JD, Lane J. Intravenous ribavirin by constant infusion for serious influenza and parainfluenza virus infection. Antivir Ther 1996; 1:5156.
  • 42
    Abed Y, Pizzorno A, Boivin G. Therapeutic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H275Y neuraminidase mutation. Antimicrob Agents Chemother 2012; 56:43754380.
  • 43
    Shetty AK, Peek LA. Peramivir for the treatment of influenza. Expert Rev Anti Infect Ther 2012; 10:123143.
  • 44
    Birnkrant D, Cox E. The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 2009; 361:22042207.
  • 45
    Ikematsu H, Kawai N. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Expert Rev Anti Infect Ther 2011; 9:851857.
  • 46
    Furuta Y, Takahashi K, Shiraki K et al. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 2009; 82:95102.
  • 47
    Triana-Baltzer GB, Gubareva LV, Nicholls JM et al. Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS ONE 2009; 4:e7788.
  • 48
    Nguyen JT, Hoopes JD, Smee DF et al. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother 2009; 53:41154126.
  • 49
    Nguyen JT, Smee DF, Barnard DL et al. Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses. PLoS ONE 2012; 7:e31006.
  • 50
    Zheng BJ, Chan KW, Lin YP et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci USA 2008; 105:80918096.
  • 51
    Sui J, Hwang WC, Perez S et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16:265273.
  • 52
    Pizzorno A, Abed Y, Boivin G. Influenza drug resistance. Semin Respir Crit Care Med 2011; 32:409422.